Lenigron

Timolol and Bimatoprost, the active ingredients in Lenigron, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are employed to lower intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension.

GNH USA supplies Lenigron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenigron, a combination of a beta‑blocker and a prostaglandin analog, is used in the management of glaucoma and ocular hypertension.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers intra‑ocular pressure to prevent conversion to glaucoma. Pseudoexfoliative glaucoma: improves pressure control when monotherapy is insufficient. Secondary open‑angle glaucoma: assists in achieving target pressure when other agents are inadequate.

Common Side Effects: - Eye irritation or burning sensation. - Transient blurred vision. - Conjunctival hyperemia (redness). - Itching or mild allergic reaction on the ocular surface. - Dry eye sensation. - Temporary increase in eyelash growth.

Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis). - Significant worsening of glaucoma or sudden loss of vision. - Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm. - Persistent ocular inflammation or uveitis. - Corneal ulceration or severe keratitis.

Before initiating Lenigron, clinicians should consider the following precautions: - Assess cardiovascular status: timolol may affect heart rate and blood pressure. - Screen for respiratory disease: avoid in patients with asthma or COPD. - Monitor intra‑ocular pressure regularly to ensure therapeutic response. - Avoid use in individuals with known hypersensitivity to beta‑blockers or prostaglandin analogs. - Store at room temperature: keep in the original container, protect from light and moisture.

Lenigron may interact with other medicines as follows:

Major Interactions (Avoid): - Non‑selective beta‑blocker antagonists (e.g., propranolol): additive systemic beta‑blockade. - Sympathomimetic agents (e.g., epinephrine eye drops): may reduce timolol efficacy. - Other prostaglandin analogs: increased risk of ocular hyperemia.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors: additive intra‑ocular pressure‑lowering effect. - Systemic antihypertensives: may enhance timolol's hypotensive action. - Topical anesthetics: may increase corneal toxicity when used together.